JAÈøÆ»Áí¹çɱ¡¤Ç¤ÏÀ¸Ì¿¤Îº¤µ¤È¿Í´Ö°¦¤ò´ðÄ´¤Ë¡¢°å»Õ¡¦´Ç¸î»Õ¤È¤â¤ËÎϤò¹ç¤ï¤»¡¢É¤á¤ë¿Í¡¹¤ò¼é¤ê¡¢ÃÏ°è¤Î´ð´´É±¡¤È¤·¤Æ¤Î¼«³Ð¤ò»ý¤Á¡¢¾ï¤Ë¿·¤·¤¯¤è¤ê¹â¤¤Ãμ±¤Î½¬ÆÀ¤Èµ»½Ñ¤Î¸¦ïÓ¤ËÎå¤ß¤Þ¤¹¡£

JAÈøÆ»Áí¹çɱ¡

¥Û¡¼¥à ¡ä°åÎÅ´Ø·¸¼Ô¤ÎÊý¤Ø ¡äÃø½ñ¡¦³Ø²ñ¡¦ÏÀʸ

Ãø½ñ¡¦³Ø²ñ¡¦ÏÀʸ

ÅöÈøÆ»Áí¹çɱ¡¡¢¤ª¤è¤Ó³Æ°å»Õ¤Ë¤è¤Ã¤Æȯɽ¤µ¤ì¤¿Ãø½ñ¡¢³Ø²ñ¤Ç¤ÎȯɽÏÀʸ¤Ê¤É¤ò¸ø³«¤·¤Æ¤¤¤Þ¤¹¡£

ÈøÆ»Áí¹çɱ¡¡¦Ãø½ñ¡¦³Ø²ñ¡¦ÏÀʸ
 

[ ¸ÆµÛ´ïÆâ²Ê ] ¤Ë¤è¤ëÃø½ñ¡¦³Ø²ñ¡¦ÏÀʸ

¡ÖÃø½ñ¡×¡Ö³Ø²ñ¡×¡ÖÏÀʸ¡×¤ÎʬÌî¤Ëʬ¤«¤ì¤Æ¤¤¤Þ¤¹¡£¤´´õ˾¤ÎʬÌî¤ò¥¯¥ê¥Ã¥¯¤¹¤ë¤È°ìÍ÷¤¬É½¼¨¤µ¤ì¤Þ¤¹¡£

¥Ç¡¼¥¿¹Ê¹þ
¥­¡¼¥ï¡¼¥É

!¹¹¿·Æü¡§2025/02/21

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2024
ÏÀʸ¥¿¥¤¥È¥ë Ç٤γÈÄ¥¾ã³²¤òÄ褷¤¿¶»Ë쥢¥ß¥í¥¤¥É¡¼¥·¥¹¤Î£±Îã
»¨»ï¥¿¥¤¥È¥ë ÆüËܸƵ۴ï³Ø²ñ»ï¡¤13
¥Ú¡¼¥¸ÈÖ¹æ 83-87
Ãø¼Ô ³ÑËÜ¿µ¼£
¶¦Ãø ¼ÂÌÊ¡¡·Ä¡¤Â¿ÅÄ¿µÊ¿¡¤Ë̸¶ÎÉÍΡ¤¿·Ã«µ®ÍΡ¤¹â³¸¼÷ϯ

!¹¹¿·Æü¡§2025/02/21

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2023
ÏÀʸ¥¿¥¤¥È¥ë Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
»¨»ï¥¿¥¤¥È¥ë Cancer Rep¡¤6¡Ê4¡Ë
¥Ú¡¼¥¸ÈÖ¹æ e1793
Ãø¼Ô Hamai K
¶¦Ãø Miyake S¡¤Tada S¡¤Fujita S¡¤Hirakawa T¡¤Matsumura M¡¤Ueno S¡¤Tanimoto T¡¤Ishikawa N

!¹¹¿·Æü¡§2025/02/21

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2023
ÏÀʸ¥¿¥¤¥È¥ë Comprehensive genomic profiling of Japanese patients with thoracic malignancies¡§A single-center retrospective study
»¨»ï¥¿¥¤¥È¥ë Respir Investig¡¤61¡Ê6¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 746-754
Ãø¼Ô Hirakawa T
¶¦Ãø Doi M¡¤Hamai K¡¤Katsura R¡¤Miyake S¡¤Fujita S¡¤Ueno S¡¤Masuda K¡¤Tanimoto T¡¤Nishisaka T¡¤ Hinoi T¡¤Hirasawa A¡¤Ishikawa N

!¹¹¿·Æü¡§2025/02/21

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2023
ÏÀʸ¥¿¥¤¥È¥ë Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
»¨»ï¥¿¥¤¥È¥ë Sci Rep¡¤13¡Ê1¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 19729
Ãø¼Ô Masuda T
¶¦Ãø Miura S¡¤Sato Y¡¤Tachihara M¡¤Bessho A¡¤Nakamura A¡¤Miyawaki T¡¤Yoshimine K¡¤Mori M¡¤ Shiraishi H¡¤Hamai K¡¤Haratani K¡¤Maeda S¡¤Tabata E¡¤Kitagawa C¡¤Tanizaki J¡¤Imai T¡¤Nogami S¡¤ Yamamoto N¡¤Nakagawa K¡¤Hattori N

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë µÞÀ­¤Î·Ð²á¤Ç»àË´¤·¤¿µÞÀ­´Ö¼ÁÇÙ±ê¤Î°ìÎã
»¨»ï¥¿¥¤¥È¥ë ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¥32
¥Ú¡¼¥¸ÈÖ¹æ 35-39
Ãø¼Ô º¬ËÜÍÛºÚ
¶¦Ãø ËÌÅçÂóÇÏ¡¤ËÌÅç¿¿µª»Ò¡¤Ìî¼¹¸À¸¡¤Àîºê¹­Ê¿¡¤ÎëÌÚÊþ»Ò¡¤ÊƸ¶½¤¼£¡¤À¾Åĸ­»Ê¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë ¿ÕÀ¸¸¡¤¬¿ÇÃǤηÀµ¡¤È¤Ê¤Ã¤Æ¥¨¥Á¥ì¥ó¥°¥ê¥³¡¼¥ëÃæÆǤΣ±Îã
»¨»ï¥¿¥¤¥È¥ë ¹­Åç°å³Ø¡¥73(7)
¥Ú¡¼¥¸ÈÖ¹æ 299-302
Ãø¼Ô ²¬ÅèÎÜÆà
¶¦Ãø »³ËÜæÆÂÀϺ¡¤»³ËÜÎÃÂÀϺ¡¤ÏÆËÜ¡¡°°¡¤Ç÷ͧµª»Ò¡¤

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Association Between Patient Preference for Inhaler Medications and Asthma Outcomes.
»¨»ï¥¿¥¤¥È¥ë J Asthma Allergy. 15
¥Ú¡¼¥¸ÈÖ¹æ 1539-1547
Ãø¼Ô Nakanishi Y¡¥
¶¦Ãø Iwamoto H¡¤Miyamoto S¡¤Nakao S¡¤Higaki N¡¤Yamaguchi K¡¤Sakamoto S¡¤Horimasu Y¡¤Masuda T¡¤Matsumoto N¡¤Nakashima T¡¤Onari Y¡¤Fujitaka K¡¤Haruta Y¡¤Hamada H¡¤Hozawa S¡¤Hattori N¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer
»¨»ï¥¿¥¤¥È¥ë Cancers¡¥14¡Ê24¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 6236
Ãø¼Ô Daido W¡¥
¶¦Ãø Masuda T¡¤Imano N¡¤Matsumoto N¡¤Hamai K¡¤Iwamoto Y¡¤Takayama Y¡¤Ueno S¡¤Sumii M¡¤Shoda H¡¤Ishikawa N¡¤Yamasaki M¡¤Nishimura Y¡¤Kawase S¡¤Shiota N¡¤Awaya Y¡¤ Suzuki T¡¤Kitaguchi S¡¤Fujitaka K¡¤Nagata Y¡¤Hattori N¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter¡¤ prospective¡¤ observational study¡ÊRising-VTE/NEJ037 study¡Ë
»¨»ï¥¿¥¤¥È¥ë Ther Adv Med Oncol¡¥14
Ãø¼Ô Tsubata Y¡¥
¶¦Ãø Hotta T¡¤Hamai K¡¤Furuya N¡¤Yokoyama T¡¤Saito R¡¤Nakamura A¡¤Masuda T¡¤Hamaguchi M¡¤Kuyama S¡¤Honda R¡¤Senoo T¡¤Nakanishi M¡¤Yamasaki M¡¤Ishikawa N¡¤Fujitaka K¡¤Kubota T¡¤Ohtsu H¡¤Kobayashi K¡¤Isobe T¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study¡¥
»¨»ï¥¿¥¤¥È¥ë Intern Med¡¥61¡Ê11¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 1663-1671
Ãø¼Ô Isoyama S¡¥
¶¦Ãø Ishikawa N¡¤Hamai K¡¤Matsumura M¡¤Kobayashi H¡¤Nomura A¡¤Ueno S¡¤Tanimoto T¡¤Maeda H¡¤Iwamoto H¡¤Hattori N¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1¡¥
»¨»ï¥¿¥¤¥È¥ë ¡¡Thorac Cancer¡¥13¡Ê11¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 1663-1671
Ãø¼Ô Masuda T¡¥
¶¦Ãø Fujitaka K¡¤Suzuki T¡¤Hamai K¡¤Matsumoto N¡¤Matsumura M¡¤Isoyama S¡¤Ueno S¡¤Mito M¡¤Yamaguchi K¡¤Sakamoto S¡¤Kawano R¡¤Masuda K¡¤Nishino R¡¤Ishikawa N¡¤Yamasaki M¡¤Hattori N¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study¡¥
»¨»ï¥¿¥¤¥È¥ë Respir Investig¡¥60(3)
¥Ú¡¼¥¸ÈÖ¹æ 418-424
Ãø¼Ô Tanimoto T¡¥
¶¦Ãø Tada S¡¤Fujita S¡¤Hirakawa T¡¤Matsumura M¡¤Isoyama S¡¤Ueno S¡¤Hamai K¡¤Tsuji N¡¤Hirosawa H¡¤Taniguchi T¡¤Okamoto T¡¤Omoto T¡¤Kusunoki S¡¤Maeda H¡¤Ishikawa N¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study¡¥
»¨»ï¥¿¥¤¥È¥ë J Hematol Oncol¡¥15(1)
¥Ú¡¼¥¸ÈÖ¹æ 40
Ãø¼Ô Tsubata Y¡¥
¶¦Ãø Hotta T¡¤Hamai K¡¤Furuya N¡¤Yokoyama T¡¤Saito R¡¤Nakamura A¡¤Masuda T¡¤maguchi M¡¤Kuyama S¡¤Honda R¡¤Senoo T¡¤Nakanishi M¡¤Yamasaki M¡¤Ishikawa N¡¤Fujitaka K¡¤Kubota T¡¤Kobayashi K¡¤Isobe T¡¥

!¹¹¿·Æü¡§2023/12/29

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2022
ÏÀʸ¥¿¥¤¥È¥ë Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer¡¥
»¨»ï¥¿¥¤¥È¥ë BMC Pulm Med¡¥22¡Ê1¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 260
Ãø¼Ô Watari N¡¥
¶¦Ãø Yamaguchi K¡¤Terada H¡¤Hamai K¡¤Masuda K¡¤Nishimura Y¡¤Sakamoto S¡¤Masuda T¡¤ ¡¡¡¡Horimasu Y¡¤Miyamoto S¡¤Nakashima T¡¤Iwamoto H¡¤Shoda H¡¤Ishikawa N¡¤Fujitaka K¡¤Miyazaki K¡¤Miyata Y¡¤Hamada H¡¤Awai K¡¤Hattori N¡¥

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë ¼¨¤·µÞ®¤Ë¸ÆµÛÉÔÁ´¤¬¿Ê¹Ô¤·¤¿ÆÃȯÀ­´ï¼Á²½ÇÙ±ê¤Î°ìÎã
»¨»ï¥¿¥¤¥È¥ë ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31
¥Ú¡¼¥¸ÈÖ¹æ 79¡Ý84
Ãø¼Ô ¡ÊÆâÆ£¿­¾¼¡Ë
¶¦Ãø ¡ÊËÌÅç¿¿µª»Ò¡Ë¡¤¡Ê±öëºéÀé»Ò¡Ë¡¤ÎëÌÚÊþ»Ò¡¤¡ÊÀ¾Åĸ­»Ê¡Ë

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë ¥¹¥Æ¥í¥¤¥ÉÃæ»ß¸å¤ËºÆȯ¤·¤¿ Pulmonary Hyalinizing Granuloma ¤Î£±Îã
»¨»ï¥¿¥¤¥È¥ë ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31
¥Ú¡¼¥¸ÈÖ¹æ 15¡Ý19
Ãø¼Ô ¡ÊËÌÅç¿¿µª»Ò¡Ë
¶¦Ãø ¡Ê±öëºéÀé»Ò¡Ë¡¤Ìî¼¹¸À¸¡¤ËÌÅçÂó¿¿¡¤Àîºê¹­Ê¿¡¤ÎëÌÚÊþ»Ò¡¤»³ÌÚ¡¡¼Â¡¤¡ÊÀ¾Åĸ­»Ê¡Ë

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë ´âÀ­Ê¢Ëì´â¤¬µ¿¤ï¤ì¤¿·ë³ËÀ­¶»Ê¢Ëì±ê¤Î£±Îã
»¨»ï¥¿¥¤¥È¥ë ¹­Åç°å³Ø¡¡74¡Ê8¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 385¡Ý389
Ãø¼Ô ËÌÅçÂó¿¿
¶¦Ãø ¡Ê±öëºéÀé»Ò¡Ë¡¤Ìî¼¹¸À¸¡¤¡ÊËÌÅç¿¿µª»Ò¡Ë¡¤Àîºê¹­Ê¿¡¤ÎëÌÚÊþ»Ò¡¤¡ÊË̺ꡡľ¡Ë,ÊƸ¶½¤¼£

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë ¤Ú¥à¥Ö¥í¥ê¥º¥Þ¥Ö¤Ë¤è¤ë MPO-ANCA ÍÛÀ­¤ÎÇÙ˦½Ð·ì¤Î£±Îã
»¨»ï¥¿¥¤¥È¥ë Æü¸ÆµÛ»ï¡¡10¡Ê3¡Ë
¥Ú¡¼¥¸ÈÖ¹æ 283¡Ý287
Ãø¼Ô ¡ÊËÌÅç¿¿µª»Ò¡Ë

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë Aspergillosis-Associated Pulmonary Oxalosis Successfully Treated with Corticosteroid Therapy: A Case
Report
»¨»ï¥¿¥¤¥È¥ë ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31
¥Ú¡¼¥¸ÈÖ¹æ 21¡Ý25
Ãø¼Ô ¡ÊShioya S¡Ë
¶¦Ãø Nomura A¡¤¡ÊKitajima M¡Ë¡¤Kitajima T¡¤Kawasaki K¡¤Suzuki T¡¤Yonehara S

!¹¹¿·Æü¡§2023/04/28

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2021
ÏÀʸ¥¿¥¤¥È¥ë IL-18
binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis
»¨»ï¥¿¥¤¥È¥ë PLoS One¡¥16(6¡Ë
¥Ú¡¼¥¸ÈÖ¹æ e0252594
Ãø¼Ô Nakanishi Y
¶¦Ãø Horimasu Y¡Ë¡¤¡ÊYamaguchi K¡Ë¡¤¡ÊSakamoto S¡Ë¡¤¡ÊMasuda T¡Ë¡¤¡ÊNakashima T¡Ë¡¤¡ÊMiyamoto S¡Ë¡¤¡ÊIwamoto H¡Ë¡¤¡ÊOhshimo S¡Ë¡¤¡ÊFujitaka K¡Ë¡¤¡ÊHamada H¡Ë¡¤¡ÊHattori N¡Ë

!¹¹¿·Æü¡§2016/02/01

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯ 2015
ÏÀʸ¥¿¥¤¥È¥ë ½Ñ¸åÉÂÍý¸¡ºº¤Ë¤Æ¿ÇÃǤµ¤ì¤¿ÇÙ¥¤¥Ì»å¾õÃî¾É
¥Ú¡¼¥¸ÈÖ¹æ 76¡Ý79
Ãø¼Ô ÃÝ°æÂçÍ´
¶¦Ãø »³ÌÚ¡¡¼Â¡¤Â§¹ÔÉÒÀ¸¡¤ÃݸµÍºµª¡¤²ÏÅççýÀ¡¡¤óîƣε½õ¡¤º´¡¹ÅÄãÀ®¡¤µÈÅÄ¡¡À¿¡¤Å·Ìî¿ÒĪ¡¤Ê¡ÅÄÉÒ¾¡¡¤Ã渶²í¹À¡¤±×ÅÄ¡¡·ò

!¹¹¿·Æü¡§2011/05/01

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯÅÙ 2011
ÏÀʸ¥¿¥¤¥È¥ë Change in serum KL-6 level from baseline is useful predicting life-threatening EGFR-TKIs induced interstitial lung disease
»¨»ï¥¿¥¤¥È¥ë Respir Res
¥Ú¡¼¥¸ÈÖ¹æ 26, 97
Ãø¼Ô (Kawase S)
¶¦Ãø (Hattori N),(Ishikawa N),(Horimasu Y),(Fujitaka K), Furonaka O, (Isobe T),(Miyoshi S),(Hamada H),(Yamane T),(Yokoyama A),(Kohno N)

!¹¹¿·Æü¡§2011/05/01

¿ÇÎÅ²Ê ¸ÆµÛ´ïÆâ²Ê
ǯÅÙ 2011
ÏÀʸ¥¿¥¤¥È¥ë ٨ʿ¾åÈé´â¤ò½ü¤¯È󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥Ù¥Ð¥·¥º¥Þ¥ÖÎÅË¡¤ÎŬ±þ´ð½à¤Ë´Ø¤¹¤ë¸¡Æ¤
»¨»ï¥¿¥¤¥È¥ë ¹­Åç°å³Ø
¥Ú¡¼¥¸ÈÖ¹æ 173-176
Ãø¼Ô É÷ϤÃ潤
¶¦Ãø ¼ÂÌÊ·Ä¡¢Âç·îÂëɧ
µá¿Í¾ðÊó¤Î¤ªÃΤ餻 Åö±¡¤Ï(ºâ)ÆüËÜ°åÎÅɾ²Áµ¡¹½¤Ë¤è¤ëǧÄê¤ò¼õ¤±¤Æ¤¤¤Þ¤¹¡£

JAÈøÆ»Áí¹çɱ¡Î×¾²²Ê¤Î¥Õ¥§¥¤¥¹¥Ö¥Ã¥¯ Î×¾²²Ê

JAÈøÆ»Áí¹çɱ¡Î×¾²¸¦½¤²Ê¤Î¥Õ¥§¥¤¥¹¥Ö¥Ã¥¯ Î×¾²¸¦½¤²Ê

JAÈøÆ»Áí¹çɱ¡ »Ô̱¸ø³«¹ÖºÂ »Ô̱¤Î¤¿¤á¤Î¤¬¤óºÇÁ°Àþ

JAÈøÆ»Áí¹çɱ¡ ÇÛ¿®Æ°²è°ìÍ÷

 
¥Ú¡¼¥¸ÀèƬ¤ØÌá¤ë